The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) plus carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple-negative breast cancer (TNBC).
Jessica Nicole Snider
No relevant relationships to disclose
Jasgit C. Sachdev
Research Funding - Celgene; Genentech
Jeffrey Warren Allen
No relevant relationships to disclose
Lee Steven Schwartzberg
Honoraria - Roche
Robyn R. Young
Consultant or Advisory Role - Celgene
Honoraria - Genentech
Ahmed Yasir Javed
No relevant relationships to disclose
Furhan Yunus
No relevant relationships to disclose
Carmel S. Verrier
No relevant relationships to disclose
Mohammad Jahanzeb
No relevant relationships to disclose